Literature DB >> 30961955

Clinical characteristics and etiologies of bronchiectasis in Korean children: A multicenter retrospective study.

Eun Lee1, Jung Yeon Shim2, Hyung Young Kim3, Dong In Suh4, Yun Jung Choi5, Man Young Han6, Kyung Suk Baek6, Ji-Won Kwon7, Joongbum Cho8, Minyoung Jung8, Young Suh Kim9, In Suk Sol9, Bong-Seong Kim10, Eun Hee Chung11, Sooyoung Lee12, Kyunguk Jeong12, Yoon Young Jang13, Gwang Cheon Jang14, Myung Chul Hyun15, Hyeon-Jong Yang16, Meeyong Shin17, Jin Tack Kim18, Ja Hyeong Kim19, Yoon Ha Hwang20, Ji Young Ahn21, Ju-Hee Seo22, Jin A Jung23, Hwan Soo Kim18, Moo Young Oh24, Yang Park25, Mi-Hee Lee26, So-Yeon Lee27, Sungsu Jung27, Soo-Jong Hong28, Young Min Ahn29.   

Abstract

BACKGROUND: Bronchiectasis is a chronic pulmonary disease characterized by progressive and irreversible bronchial dilatation. The aim of the present study was to investigate the etiologies and clinical features of bronchiectasis in Korean children.
METHODS: We performed a retrospective review of the medical records for children diagnosed with bronchiectasis between 2000 and 2017 at 28 secondary or tertiary hospitals in South Korea.
RESULTS: A total of 387 cases were enrolled. The mean age at diagnosis was 9.2 ± 5.1 years and 53.5% of the patients were boys. The most common underlying cause of bronchiectasis was preexisting respiratory infection (55.3%), post-infectious bronchiolitis obliterans (14.3%), pulmonary tuberculosis (12.3%), and heart diseases (5.6%). Common initial presenting symptoms included chronic cough (68.0%), recurrent pneumonia (36.4%), fever (31.1%), and dyspnea (19.7%). The most predominantly involved lesions were left lower lobe (53.9%), right lower lobe (47.1%) and right middle lobe (40.2%). No significant difference was observed in the distribution of these involved lesions by etiology. The forced expiratory volume in 1 s (FEV1) levels were lowest in cases with interstitial lung disease-associated bronchiectasis, followed by those with recurrent aspiration and primary immunodeficiency.
CONCLUSIONS: Bronchiectasis should be strongly considered in children with chronic cough and recurrent pneumonia. Long-term follow-up studies on pediatric bronchiectasis are needed to further clarify the prognosis and reduce the disease burden in these patients.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Bronchiectasis; Children; Etiology; Lung function; Prognosis

Mesh:

Year:  2019        PMID: 30961955     DOI: 10.1016/j.rmed.2019.01.018

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  3 in total

1.  Long-term macrolide treatment for non-cystic fibrosis bronchiectasis in children: a meta-analysis.

Authors:  Eun Lee; In Suk Sol; Jong Deok Kim; Hyeon-Jong Yang; Taek Ki Min; Gwang Cheon Jang; Yoon Ha Hwang; Hyun-Ju Cho; Dong In Suh; Kyunghoon Kim; Hwan Soo Kim; Yoon Hee Kim; Sung Il Woo; Yong Ju Lee; Sungsu Jung; You Hoon Jeon
Journal:  Sci Rep       Date:  2021-12-20       Impact factor: 4.379

2.  Follow-up on the therapeutic effects of a budesonide, azithromycin, montelukast, and acetylcysteine (BAMA) regimen in children with post-infectious bronchiolitis obliterans.

Authors:  Tingting Weng; Xixi Lin; Leying Wang; Jiamei Lv; Lin Dong
Journal:  J Thorac Dis       Date:  2021-08       Impact factor: 2.895

Review 3.  Bronchiectasis in African children: Challenges and barriers to care.

Authors:  Charl Verwey; Diane M Gray; Ziyaad Dangor; Rashida A Ferrand; Adaeze C Ayuk; Diana Marangu; Sandra Kwarteng Owusu; Muntanga K Mapani; Ameena Goga; Refiloe Masekela
Journal:  Front Pediatr       Date:  2022-07-25       Impact factor: 3.569

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.